Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today? [Seeking Alpha]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Seeking Alpha
NVAX leverages partnerships with Sanofi and Pfizer, targeting ~$500m annual revenues by 2030, with a forward P/S of ~3x and P/E of ~7.5x. MRNA's growth depends on COVID/flu combo vaccine, intismeran cancer program, and RSV vaccine, but faces higher risk due to elevated spending and lack of major partners. I am cautiously bullish on both: NVAX for stability and incremental growth, MRNA for higher risk/reward tied to late-stage pipeline execution. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » 35007/E+ via Getty Images Investment Overview - Background to Moderna / Novavax Five years ago, Moderna, Inc. ( MRNA ) and Novavax, Inc. ( NVAX ) were two of the most talked about stocks across platforms like Seeking Alpha, social media, and More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and c
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline [Yahoo! Finance]Yahoo! Finance
- Novavax (NASDAQ:NVAX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NVAX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- Will Licensing Novavax's Matrix-M Adjuvant Reshape Pfizer's (PFE) Vaccine Platform Strategy? [Yahoo! Finance]Yahoo! Finance
- Why Are Novavax (NVAX) Shares Soaring Today [Yahoo! Finance]Yahoo! Finance
- Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer [Yahoo! Finance]Yahoo! Finance
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 1/26/26 - Form 4
- 1/20/26 - Form 8-K
- 1/12/26 - Form 8-K
- NVAX's page on the SEC website